Skip to main content

Table 1 Characteristics of the study population

From: Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis

Variable All patients (N = 157)
Sepsis criteria 157 (100.0)
 Sepsis, N (%) 112 (71.3)
 Septic shock, N (%) 45 (28.7)
Patients enrollment
 Intensive care unit, N (%) 94 (59.9)
 Emergency room, N (%) 63 (40.1)
Age (years), median [IQR] 70 [57.7–77.0]
Males, N (%) 95 (60.5)
Hospital stay (days), median [IQR] 16 [8–40]
In-hospital mortality, N (%) 40 (25.5)
30-day mortality, N (%) 34 (21.7)
Comorbidities
 Hemato-oncologic, N (%) 31 (19.6)
 Pulmonary, N (%) 29 (18.6)
 Cerebrovascular, N (%) 28 (17.5)
 Renal and genitourinary, N (%) 19 (12.4)
 Gastrointestinal, N (%) 18 (11.3)
 Cardiovascular, N (%) 16 (10.3)
 Others, N (%) 16 (10.3)
Type of infections/proportion of infection episodes with isolated pathogens*
 Bacteremia, N (%)/% 90 (57.3)/100%
 Respiratory infection, N (%)/% 102 (65.0)/88.2%
 Urinary infection, N (%)/% 55 (35.0)/100%
 Gastrointestinal infection, N (%)/% 26 (16.6)/46.2%
 Others, N (%)/% 4 (2.5)/100%
eGFR by MDRD Study equation (mL/min/1.73 m2), median [IQR] 44.45 [20.83–81.33]
SOFA score range 2–11
  2 (45, 28.7%); 3 (32, 20.4%); 4 (26, 16.6%); 5 (14, 8.9%); 6 (13, 8.3%); 7 (12, 7.6%); 8 (6, 3.8%); 9 (3, 1.9%); 10 (3, 1.9%); 11 (3, 1.9%)
CRP (mg/dL), median [IQR] 12.54 [7.22–22.0]
WBC (× 109/L), median [IQR] 12.47 [8.18–17.10]
PCT (ng/mL), median [IQR] 6.19 [2.25–21.99]
Presepsin (pg/mL), median [IQR] 2714.0 [1479.3–4129.7]
Galectin-3 (ng/mL), median [IQR] 30.8 [17.9–58.5]
sST2 (ng/mL), median [IQR] 214.5 [133.6–238.8]
  1. * Multiple infections were observed in 112 patients (71.3%), and 20 patients (12.7%) had radiographically proven infection without pathogen isolation. The number of type of infections and proportion of infection episode with isolated pathogen is based on each infection episode
  2. IQR interquartile range, eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease, SOFA sequential organ failure assessment, PCT procalcitonin, sST2 soluble suppression of tumorigenicity 2